Lower limb revascularization for PAD using a heparin-coated PTFE conduit

Melissa L. Kirkwood, Grace J. Wang, Benjamin M. Jackson, Michael A. Golden, Ronald M. Fairman, Edward Y. Woo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants-56% male; mean age 69. Comorbidities included hypertension (HTN; 81%), hyperlipidemia (72%), coronary artery disease (CAD; 74%), and smoking (59%). Most patients were Rutherford category 4 or higher. A total of 34% of patients had only 1 runoff vessel; 10% of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4±8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0% and 86.0% at 30 days and 18 months, respectively. Limb salvage at 30 days was 95%, and at 18 months was 90%. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.

Original languageEnglish (US)
Pages (from-to)329-334
Number of pages6
JournalVascular and Endovascular Surgery
Volume45
Issue number4
DOIs
StatePublished - May 2011

Fingerprint

Polytetrafluoroethylene
Heparin
Lower Extremity
Transplants
Nociceptive Pain
Thrombectomy
Limb Salvage
Peripheral Vascular Diseases
Hyperlipidemias
Blood Vessels
Comorbidity
Coronary Artery Disease
Extremities
Smoking
Hypertension

Keywords

  • Heparin bonded ePTFE
  • Lower extremity bypass
  • PROPATEN

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Lower limb revascularization for PAD using a heparin-coated PTFE conduit. / Kirkwood, Melissa L.; Wang, Grace J.; Jackson, Benjamin M.; Golden, Michael A.; Fairman, Ronald M.; Woo, Edward Y.

In: Vascular and Endovascular Surgery, Vol. 45, No. 4, 05.2011, p. 329-334.

Research output: Contribution to journalArticle

Kirkwood, Melissa L. ; Wang, Grace J. ; Jackson, Benjamin M. ; Golden, Michael A. ; Fairman, Ronald M. ; Woo, Edward Y. / Lower limb revascularization for PAD using a heparin-coated PTFE conduit. In: Vascular and Endovascular Surgery. 2011 ; Vol. 45, No. 4. pp. 329-334.
@article{efe42d2158e04b89a4dcf1bee87343c7,
title = "Lower limb revascularization for PAD using a heparin-coated PTFE conduit",
abstract = "Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants-56{\%} male; mean age 69. Comorbidities included hypertension (HTN; 81{\%}), hyperlipidemia (72{\%}), coronary artery disease (CAD; 74{\%}), and smoking (59{\%}). Most patients were Rutherford category 4 or higher. A total of 34{\%} of patients had only 1 runoff vessel; 10{\%} of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4±8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0{\%} and 86.0{\%} at 30 days and 18 months, respectively. Limb salvage at 30 days was 95{\%}, and at 18 months was 90{\%}. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.",
keywords = "Heparin bonded ePTFE, Lower extremity bypass, PROPATEN",
author = "Kirkwood, {Melissa L.} and Wang, {Grace J.} and Jackson, {Benjamin M.} and Golden, {Michael A.} and Fairman, {Ronald M.} and Woo, {Edward Y.}",
year = "2011",
month = "5",
doi = "10.1177/1538574411401757",
language = "English (US)",
volume = "45",
pages = "329--334",
journal = "Vascular and Endovascular Surgery",
issn = "1538-5744",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Lower limb revascularization for PAD using a heparin-coated PTFE conduit

AU - Kirkwood, Melissa L.

AU - Wang, Grace J.

AU - Jackson, Benjamin M.

AU - Golden, Michael A.

AU - Fairman, Ronald M.

AU - Woo, Edward Y.

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants-56% male; mean age 69. Comorbidities included hypertension (HTN; 81%), hyperlipidemia (72%), coronary artery disease (CAD; 74%), and smoking (59%). Most patients were Rutherford category 4 or higher. A total of 34% of patients had only 1 runoff vessel; 10% of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4±8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0% and 86.0% at 30 days and 18 months, respectively. Limb salvage at 30 days was 95%, and at 18 months was 90%. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.

AB - Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants-56% male; mean age 69. Comorbidities included hypertension (HTN; 81%), hyperlipidemia (72%), coronary artery disease (CAD; 74%), and smoking (59%). Most patients were Rutherford category 4 or higher. A total of 34% of patients had only 1 runoff vessel; 10% of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4±8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0% and 86.0% at 30 days and 18 months, respectively. Limb salvage at 30 days was 95%, and at 18 months was 90%. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.

KW - Heparin bonded ePTFE

KW - Lower extremity bypass

KW - PROPATEN

UR - http://www.scopus.com/inward/record.url?scp=80052770029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052770029&partnerID=8YFLogxK

U2 - 10.1177/1538574411401757

DO - 10.1177/1538574411401757

M3 - Article

C2 - 21444347

AN - SCOPUS:80052770029

VL - 45

SP - 329

EP - 334

JO - Vascular and Endovascular Surgery

JF - Vascular and Endovascular Surgery

SN - 1538-5744

IS - 4

ER -